psilocybin
Spotlight: Depression remission endures 5 years after psilocybin trial consisting of psilocybin with psychotherapy (2025)
"when it comes to reducing depression with psychedelic-assisted therapy, what matters even more than the drug is a strong relationship between the therapist and study participant."
Reducción de Daños Psicodélicos
La Reducción de Daños Psicodélicos
La Reducción de Daños Psicodélicos comienza con la educación
dmt
Spotlight: N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences (Vohryzek, et al, 2025)
"the connectome harmonic repertoire under N,N-dimethyltryptamine (DMT) is reshaped in line with other reported psychedelic compounds - psilocybin, lysergic acid diethylamide (LSD) and ketamine... the repertoire entropy of connectome harmonics increases under DMT, as with those other psychedelics."
ketamine
Spotlight: "Ketamine States: A Journey Through the Mind" (Wolfson, et al, 2025)
Estados de la ketamina: Un viaje a través de la mente
ketamine
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach (Wolfson & Vaid, 2024)
"in a conducive set and settings, these experiences have been demonstrated to be of positive use in psychiatry and psychotherapy, providing a time-out from usual states of mind to facilitate a reshaping of self-experience along with symptomatic relief."
ketamine
Spotlight: Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review (Kew, et al, 2023)
"...Outcomes were largely positive for the addition of psychotherapy to ketamine treatment...The combination of psychotherapy and ketamine offers promise for the treatment of psychiatric disorders"
uruguay
INSTITUTO PSICODÉLICO DE SALUD MENTAL Y TERAPIA FAMILIAR
Un centro de estudios en psicodelia que aboga por el estudio y la práctica seguros y legales de las experiencias de la medicina psicodélica y su aplicación a la salud mental y el bienestar | Uruguay
ketamine
Spotlight: "Ketamine-Assisted Group Therapy for Work-Related Stress in First Responders and Frontline Health Care Workers" (Flynn, et al, 2025)
"Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder."
ketamine
Spotlight: Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis (Bhatt, et al, 2025)
Experiencia mística de la ketamina en veteranos con depresión resistente en tratamiento: un análisis exploratorio retrospectivo
Critique: Yale Interventional Psychiatry Grand Rounds: Ketamine and Esketamine – Is There a Meaningful Clinical Difference?
Psychiatrist Samuel Wilkinson weighs in
ketamine
Spotlight: The Effectiveness of Combining Ketamine and Cognitive Behavioural Therapy in Treating Major Depressive Disorder (2025)
" This study seeks to investigate the combined effectiveness of ketamine and CBT in the treatment of MDD, with the hypothesis that integrated treatment will outperform either modality administered alone."
ketamine
Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)
"...the real-world clinical data presented here suggest a sustained effectiveness and safety profile of longer-term ketamine treatment for up to 6 months for patients with TRD. "
ketamine
Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)
"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."
mdma
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology (Wittenkeller, et al, 2025)
"enhancing baseline dopamine while minimising excessive drug-induced dopamine surges may help normalise motivational circuits and reduce relapse risk."
psychedelic research
Spotlight: Toward Consensus in Psychedelic-Assisted Therapy: The Critical Role of Psychotherapeutic Support (Modesto-Lowe, et al, 2025)
"...psychotherapy is essential for the safety and efficacy of psychedelic-assisted therapy... Insight from naturalistic settings emphasizes the importance of group dynamics and context."
mdma
Spotlight: MDMA + Psychotherapy as a treatment for major depressive disorder: proof of principle study (Kvam, et al, 2025)
"There were no adverse events of special interest, and no unexpected or serious adverse events. The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings."
ketamine
Spotlight: From Anesthetic to Neuroprotector: Multi-Omics Reveals Ketamine's Previously Unexplored Neuroprotective Role in Alzheimer's Disease (Gong, et al, 2025)
"This integrative study identifies robust diagnostic biomarkers and nominates ketamine for repurposing in AD. Experimental validation of ketamine's neuroprotective effects and FIBP's role is warranted."
lsd
Spotlight: Single Treatment With MM120 (Lysergide) in Generalized Anxiety DisorderA Randomized Clinical Trial (Robinson, et al, 2025)
In this phase 2b, multicenter, randomized, double-blind, placebo-controlled study of 4 dose levels of MM120 (a form of LSD) that included 198 adults with generalized anxiety disorder 4 was statistically significant.
